Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H9BrN6O |
| Molecular Weight | 357.165 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
BrC1=CC=CC=C1NC(=O)NC2=CC=C(C#N)C3=C2N=NN3
InChI
InChIKey=SEDUMQWZEOMXSO-UHFFFAOYSA-N
InChI=1S/C14H9BrN6O/c15-9-3-1-2-4-10(9)17-14(22)18-11-6-5-8(7-16)12-13(11)20-21-19-12/h1-6H,(H2,17,18,22)(H,19,20,21)
| Molecular Formula | C14H9BrN6O |
| Molecular Weight | 357.165 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.karger.com/Article/Abstract/62157Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11561067
Sources: https://www.karger.com/Article/Abstract/62157
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11561067
SB-265610 is an allosteric inverse agonist of CXCR2 receptor. In a rat model it prevents hyperoxia-induced newborn lung injury by inhibiting chemotaxis of neutrophils to the lungs.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2434 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19422399 |
5.4 nM [Kd] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The hepatitis C virus core protein indirectly induces alpha-smooth muscle actin expression in hepatic stellate cells via interleukin-8. | 2010-05 |
|
| A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. | 2010-04 |
|
| SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor. | 2009-09 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11561067
In a model of hyperoxia-induced lung injury, SB-265610 was injected 1, 2, or 3 mg/kg (10, 20, or 30 μg) i.p. once daily.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11561067
Chemotaxis of isolated rat neutrophils was assessed using 48-well microchemotaxis chambers. Migration was allowed to continue for 2 h at 37°C, 5% CO2. Experiments were performed in the presence of 0 to 1000 nM SB-265610, with 100 nM CINC-1 in the lower chambers. Neutrophils were permitted to chemotax onto filters, after which the upper side was washed in phosphate-buffered saline and scraped. The lower side was stained using Wright-Giemsa. The stained filters were examined with a microscope at 100× magnification, digital images of the stained filters were obtained, and cells were counted from the printed images.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:30:40 GMT 2025
by
admin
on
Mon Mar 31 18:30:40 GMT 2025
|
| Record UNII |
9P785F0579
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
211096-49-0
Created by
admin on Mon Mar 31 18:30:40 GMT 2025 , Edited by admin on Mon Mar 31 18:30:40 GMT 2025
|
PRIMARY | |||
|
DTXSID10175339
Created by
admin on Mon Mar 31 18:30:40 GMT 2025 , Edited by admin on Mon Mar 31 18:30:40 GMT 2025
|
PRIMARY | |||
|
9P785F0579
Created by
admin on Mon Mar 31 18:30:40 GMT 2025 , Edited by admin on Mon Mar 31 18:30:40 GMT 2025
|
PRIMARY | |||
|
9841667
Created by
admin on Mon Mar 31 18:30:40 GMT 2025 , Edited by admin on Mon Mar 31 18:30:40 GMT 2025
|
PRIMARY |